Business Wire

THALES

5.6.2024 11:44:26 CEST | Business Wire | Press release

Share
Thales Now Provides Complete Passwordless Functionality for Enterprises with Passwordless 360°

Thales, the leading global technology and security provider, today announced Passwordless 360°, a new concept for passwordless authentication which offers Thales customers the broadest coverage of passwordless function across multiple types of users and assurance levels. Passwordless 360° has the flexibility to let companies use the latest technologies like FIDO passkeys, while also making the most of previous investments they might have made in passwordless technologies.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240605617393/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

©KuppingerCole

End users are increasingly frustrated with the number of passwords they’re asked to use, as well as the rules in place around their complexity. With the average person having as many as 100 to manage, users seek workarounds to get by – choosing passwords that are easier to remember or reusing the same password across multiple services.

Passwordless 360° provides a complete set of tools that let organizations use passwordless authentication across a wide range of applications - from secure access to personal and work devices, to legacy and modern web resources. This helps keep the costs of making the move to passwordless down by being able to use one system – as well as increasing the likelihood that employees, customers and suppliers will use it. By removing the need to use traditional passwords it also eliminates the associated security risks through theft and phishing. Passwordless 360° can also meet the individual risk management requirements an organization might have, adhering to NIST requirements no matter where the passkeys are stored.

Sitting alongside the existing Thales OneWelcome Identity Platform that serves as the foundation for passwordless policies, the Passwordless 360° concept includes:

  • Support for passkeys in the OneWelcome Identity Platform
  • Passwordless Windows Logon, a true passwordless user experience that replaces passwords with ways for users to identify themselves, offering convenience and security benefits.
  • SafeNet FIDO Key Manager, a way of helping users manage the several FIDO keys they might be using themselves, reducing administration costs for organizations.
  • FIDO Authenticator Lifecycle Management, developed in partnership with identity management software company Versasec. This tool lets organizations manage FIDO tokens and lets larger enterprises make the move to the modern FIDO standard at the scale needed.

The announcement comes as Thales has been named an Overall, Product, Innovation and Market Leader in KuppingerCole’s latest Leadership Compass on Passwordless Authentication for Consumers, with the platform praised for offering a versatile set of identity applications encompassing a wide range of authentication methods to meet organizations’ needs.

Alejandro Leal, Research Analyst at KuppingerCole commented: Overall, Thales offers a comprehensive solution that enables organizations to improve their identity management practices, adapt to evolving technologies, and effectively secure their systems and data. Organizations in highly regulated industries and security-conscious organizations in both the public and private sectors that require strong authentication options should consider the OneWelcome Identity Platform.”

About Thales

Thales (Euronext Paris: HO) is a global leader in advanced technologies specialized in three business domains: Defence & Security, Aeronautics & Space, and Cybersecurity & Digital identity.

It develops products and solutions that help make the world safer, greener and more inclusive.

The Group invests close to €4 billion a year in Research & Development, particularly in key innovation areas such as AI, cybersecurity, quantum technologies, cloud technologies and 6G.

Thales has close to 81,0001 employees in 68 countries. In 2023, the Group generated sales of €18.4 billion.

_______________________________

1 Excluding Transport business, which is being divested

PLEASE VISIT

Thales Group

Cloud Protection & Licensing Solutions | Thales Group

Cybersecurity Solutions | Thales Group

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240605617393/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Thales Builds Cryptographic Security for the Age of AI and Post-Quantum Computing14.9.2026 09:00:00 CEST | Press release

Thales launches Luna 8, a new hardware security module (HSM) to provide future-ready, quantum resistant security to protect critical data and applications Powered by a Thales designed cryptographic processor, it delivers unparalleled performance, enhanced protection and the flexibility to adapt to new security needs Drawing on decades of cryptographic expertise, Luna 8 combines trusted security with support for emerging technologies, including post quantum cryptography According to the 2026 Thales Data Threat Report, the threat of Harvest Now, Decrypt Later (HNDL) attacks was the top-cited risk, with 59% of organizations reporting that they are prototyping and evaluating post-quantum cryptography (PQC) algorithms to prepare for the quantum era. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260804748922/en/ ©Thales To help organizations turn this readiness into deployment,Thales, a global leader in advanced technologies, tod

U.S. FDA Accepts New Drug Application Under Priority Review for Takeda’s Zasocitinib in Moderate-to-Severe Plaque Psoriasis, with Potential to Redefine Oral Treatment Expectations14.9.2026 09:00:00 CEST | Press release

Acceptance is based on pivotal Phase 3 data demonstrating rapid, durable and consistent skin clearance, including in high-impact sites, in a convenient once-daily pill Results from nearly 3,000 patients support potential for next-generation TYK2 inhibitor to redefine oral treatment expectations in psoriasis The Prescription Drug User Fee Act (PDUFA) target action date is in the first quarter of calendar year 2027 Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) under Priority Review for zasocitinib (TAK-279) for the treatment of adults with moderate-to-severe plaque psoriasis. Zasocitinib is an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, which demonstrated rapid, durable and consistent skin clearance in Phase 3 plaque psoriasis studies.1-3 Addressing unmet needs in psoriasis treatment “Despite progress in psoriasis care, there remains a need for highly

SWISSto12 and Mitsubishi Electric Corporation Announce Strategic Partnership14.9.2026 09:00:00 CEST | Press release

The Memorandum of Understanding (MoU) and additional contract signal a new phase of collaboration on market development in the Asia Pacific (APAC) region SWISSto12 today announced a memorandum of understanding (MoU) with Mitsubishi Electric Corporation (MELCO) (TOKYO: 6503) to pursue joint opportunities on advanced payloads, radio frequency (RF) products, and market development in Japan and the APAC region. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260914982179/en/ Masahiko Arai, Executive Officer and Group President, Defense & Space Systems, Mitsubishi Electric, and Dr. Emile de Rijk, Chief Executive Officer, SWISSto12 Joint opportunities will leverage MELCO’s extensive satellite system expertise and integration capabilities together with SWISSto12’s proprietary 3D-printing designs and processes that form the foundation of its next-generation payloads—smaller, lighter, highly performant, yet built in materially shorter

Focused Support Launches Cavok STRIKE to Expand Link-16 Participation Across the Joint Force14.9.2026 07:00:00 CEST | Press release

Extending Link-16 interoperability without platform-level hardware integration Focused Support LLC today announced the launch of Cavok STRIKE, an integrated software capability that expands the Link-16 tactical battlespace picture by enabling additional operational platforms to participate in the Link-16 network. Modern battlefields have increasing numbers of unmanned systems, sensors, and supporting platforms operating throughout the joint battlespace. The rapid proliferation of Group 1, 2, and 3 UAS, including both expendable and recoverable systems, has created a growing need to integrate these assets into the broader tactical network. Many of these platforms provide operationally relevant information but have historically remained outside the Link-16 network due to limitations in size, weight, power, platform integration complexity, or acquisition cost. Cavok STRIKE addresses this gap by enabling platforms to participate in the Link-16 network as non-command-and-control participant

Fujirebio Expands Access to Blood-based Neurology Testing in Brazil with ANVISA Market Authorization for Lumipulse® G NfL Blood and Lumipulse G pTau 217 Plasma14.9.2026 07:00:00 CEST | Press release

H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio today announced that the Brazilian Health Regulatory Agency (ANVISA) has granted market authorization for the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays for use on the fully automated LUMIPULSE® G immunoassay platform in Brazil. “ANVISA authorization of the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays marks another important step in our mission to expand access to reliable, clinically meaningful blood-based biomarkers for clinicians and patients worldwide,” said Christiaan De Wilde, CEO of Fujirebio Europe N.V. “By making both neurological biomarker assays available to laboratories on a single, fully automated platform, we are helping support more informed clinical decision-making across a broad range of neurological conditions and throughout the diagnostic pathway.” The Brazilian ANVISA authorizations are based on the already CE marked in vitro diagnostics (IVD) approvals of these two

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye